Potential allergy vaccine boosts hope for sufferers

Australian scientists have developed a potential vaccine for hayfever and other pollen related allergies.

The breakthrough could provide a lifeline to the 25 percent of the world's population suffering severe allergic responses to pollen.

Working with a rye grass protein - one of the most potent environmental allergens known - the team, from the University of Melbourne's Plant Molecular Biology and Biotechnology Group, has modified the gene responsible for its production.

The modified gene produced a protein that has a significantly reduced allergenic response, yet one still capable of boosting a person's immune response. These twin features are the key to a potential vaccine, or effective immunotherapy - the practice of giving allergic patients small, but increasing doses of allergen-containing extracts to boost their immunity to the allergen.

"Skin prick tests to assess the protein's safety suggest it is a significantly safer and more effective alternative to the current immunotherapy used to treat grass pollen allergies," says Associate Professor Prem Bhalla, joint leader of the group.

Their research is published in the latest European Journal of Immunology.

Current immunotherapy carries a significant risk of lethal side effects that include anaphylactic shock, a condition where the body rapidly becomes hypersensitive to an allergen.

"The symptoms of allergenic disease, like asthma, hayfever, allergic dermatitis and conjunctivitis, can be controlled with drugs, but specific immunotherapy is the only way to treat the causes of allergies that produce a potentially life threatening hypersensitivity (Type 1 allergies), says Bhalla.

Since its introduction in 1911, immunotherapy therapy has been subject to criticism and debate largely because the underlying immunological mechanisms of the human body are still unknown and because there has been no way of controlling the contents of the allergen-containing

Contact: Jason Major
University of Melbourne

Page: 1 2 3

Related biology news :

1. Potential for enhanced sequestration of carbon in soils supports evaluations
2. Potential blood test for colon cancer risk
3. Potential new treatment for Gaucher disease developed by scientists at Scripps Research Institute
4. Potential cause of arthritis discovered
5. Potential of regenerative medicine explored
6. Potential therapy reported for children, adults with end-stage liver disease
7. Potential of tailoring drugs to genetic makeup confirmed--but challenges remain
8. Potential new anthrax therapy discovered
9. Potential gene therapy carriers created that mimic viruses, without the risk
10. New Class Of Synthetic Capsules That Mimic Biological Cells Has Wide Array Of Potential Uses
11. Role Of Protein Linked To Colon Cancer Identified, Offering Potential Target For Therapy

Post Your Comments:

(Date:6/19/2020)... ... 2020 , ... Join experts from Envigo Lauren Klaskala, Project Manager ... webinar on Wednesday, July 8, 2020 at 11am EDT (4pm BST/UK). , Nuclease-based ... models. However, while modifying the genome may be more straightforward, the challenge to create ...
(Date:6/5/2020)... ... June 04, 2020 , ... Murrieta Genomics has announced ... application for simplified sample preparation for Next Generation Genomic Sequencing (NGS) . This ... time, and complexity of sample preparation. , “I have been at the bench for ...
(Date:5/30/2020)... JOSE, Calif. (PRWEB) , ... May 29, 2020 ... ... and enabler of digital transformation for enterprises globally, has collaborated with EchoNous Inc. ... the FDA. It can measure systolic heart function, which has been clinically ...
Breaking Biology News(10 mins):
(Date:6/28/2020)... ... June 25, 2020 , ... The Indoor Lab, a ... Safe Space™ for businesses of all types to ensure cleanliness, distancing and occupancy with ... , A Safe Space™ enabled business will provide a health performance index system that ...
(Date:6/28/2020)... ... June 25, 2020 , ... Lumeda Inc. ... cancer, today announced the company has entered a license agreement with Roswell Park ... Lumeda globally exclusive rights to Roswell Park intellectual property surrounding a novel medical ...
(Date:6/23/2020)... ... 23, 2020 , ... Kerafast Inc. , developers of ... the availability of the Delta-G-VSV Pseudotyping System for coronavirus research applications. The system, ... SARS-CoV-2 viral entry and COVID-19 vaccine effectiveness at just biosafety level 2 (BSL-2) ...
(Date:6/23/2020)... (PRWEB) , ... June 22, 2020 , ... ... now offering an Amniosomes special offer. This includes buy three, get the fourth ... call (888) 568-6909. , Amniotic derived exosomes, known as exosomes, have been a ...
Breaking Biology Technology:
Cached News: